137 related articles for article (PubMed ID: 7399569)
1. The effect of cobra venom factor on alternative pathway hemolytic activity in mice.
Joiner KA; Hawiger A; Gelfand JA
Immunol Commun; 1980; 9(3):277-81. PubMed ID: 7399569
[TBL] [Abstract][Full Text] [Related]
2. The oligosaccharide chains of cobra venom factor are required for complement activation.
Grier AH; Vogel CW
Mol Immunol; 1989 Jun; 26(6):563-74. PubMed ID: 2770749
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of transgenic mice expressing cobra venom factor.
Andrä J; Halter R; Kock MA; Niemann H; Vogel CW; Paul D
Mol Immunol; 2002 Oct; 39(5-6):357-65. PubMed ID: 12220893
[TBL] [Abstract][Full Text] [Related]
4. The cobra complement system: I. The alternative pathway of activation.
Vogel CW; Müller-Eberhard HJ
Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
[TBL] [Abstract][Full Text] [Related]
5. Prolongation of cardiac xenograft survival by depletion of complement.
Leventhal JR; Dalmasso AP; Cromwell JW; Platt JL; Manivel CJ; Bolman RM; Matas AJ
Transplantation; 1993 Apr; 55(4):857-65; discussion 865-6. PubMed ID: 8475561
[TBL] [Abstract][Full Text] [Related]
6. Factors in cobra venoms affecting the complement system.
Vogt W
Toxicon; 1982; 20(1):299-303. PubMed ID: 7080043
[TBL] [Abstract][Full Text] [Related]
7. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
Van den Berg CW; Aerts PC; Van Dijk H
J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
[TBL] [Abstract][Full Text] [Related]
8. Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival.
Candinas D; Lesnikoski BA; Robson SC; Miyatake T; Scesney SM; Marsh HC; Ryan US; Dalmasso AP; Hancock WW; Bach FH
Transplantation; 1996 Aug; 62(3):336-42. PubMed ID: 8779679
[TBL] [Abstract][Full Text] [Related]
9. CVF-induced decomplementation: effect on lung transvascular protein flux after thrombin.
Johnson A; Lo SK; Blumenstock FB; Malik AB
J Appl Physiol (1985); 1987 Mar; 62(3):863-9. PubMed ID: 3032888
[TBL] [Abstract][Full Text] [Related]
10. Effects of systemic complement activation on renal circulation of rats.
Schlottmann K; Gulbins E; Rauterberg EW; Steinhausen M
Eur J Clin Invest; 1994 May; 24(5):320-30. PubMed ID: 8088308
[TBL] [Abstract][Full Text] [Related]
11. The effect of systemic decomplementation with cobra venom factor on corneal complement levels in guinea pigs.
Pleyer U; Mondino BJ; Sumner HL
Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2212-5. PubMed ID: 1607231
[TBL] [Abstract][Full Text] [Related]
12. The effects of complement depletion on corneal inflammation in rats.
Verhagen C; Breebaart AC; Kijlstra A
Invest Ophthalmol Vis Sci; 1992 Feb; 33(2):273-9. PubMed ID: 1740355
[TBL] [Abstract][Full Text] [Related]
13. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
14. Effect of complement activation with cobra venom factor on pulmonary vascular permeability.
Johnson A; Cooper JA; Malik AB
J Appl Physiol (1985); 1986 Dec; 61(6):2202-9. PubMed ID: 3027023
[TBL] [Abstract][Full Text] [Related]
15. Measurement of modulation of mouse complement levels in vivo, utilizing a microtiter hemolytic assay.
White KL; Anderson AC
Agents Actions; 1984 Dec; 15(5-6):562-8. PubMed ID: 6532179
[TBL] [Abstract][Full Text] [Related]
16. New synthetic inhibitor to the alternative complement pathway.
Ikari N; Sakai Y; Hitomi Y; Fujii S
Immunology; 1983 Aug; 49(4):685-91. PubMed ID: 6553561
[TBL] [Abstract][Full Text] [Related]
17. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
18. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation.
Zara J; Pomato N; McCabe RP; Bredehorst R; Vogel CW
Bioconjug Chem; 1995; 6(4):367-72. PubMed ID: 7578355
[TBL] [Abstract][Full Text] [Related]
19. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
[TBL] [Abstract][Full Text] [Related]
20. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
Hodgetts SI; Grounds MD
Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
